[{"id":"dfb4196c-a977-4285-8b52-26ba36ee3448","acronym":"","url":"https://clinicaltrials.gov/study/NCT07476287","created_at":"2026-03-28T01:40:30.305Z","updated_at":"2026-03-28T01:40:30.305Z","phase":"Phase 2","brief_title":"Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer","source_id_and_acronym":"NCT07476287","lead_sponsor":"Pfizer","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/15/2026","start_date":" 05/15/2026","primary_txt":" Primary completion: 03/19/2028","primary_completion_date":" 03/19/2028","study_txt":" Completion: 03/19/2031","study_completion_date":" 03/19/2031","last_update_posted":"2026-03-17"},{"id":"ce020719-ee60-4c78-aac1-c9da91de0268","acronym":"GIVEN","url":"https://clinicaltrials.gov/study/NCT07472478","created_at":"2026-03-28T01:39:49.899Z","updated_at":"2026-03-28T01:39:49.899Z","phase":"Phase 2","brief_title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","source_id_and_acronym":"NCT07472478 - GIVEN","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Anfangning (garsorasib) • Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2026-03-16"},{"id":"a6d31c69-7c36-43a0-bc25-c25fb37e0176","acronym":"AGA TKI NSCLC","url":"https://clinicaltrials.gov/study/NCT07158840","created_at":"2025-09-13T08:44:13.914Z","updated_at":"2025-09-13T08:44:13.914Z","phase":"Phase 2","brief_title":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment","source_id_and_acronym":"NCT07158840 - AGA TKI NSCLC","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/05/2025","start_date":" 09/05/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-09-08"},{"id":"fae12559-05ff-4175-9322-233f03620f30","acronym":"","url":"https://clinicaltrials.gov/study/NCT07159828","created_at":"2025-09-13T08:45:52.032Z","updated_at":"2025-09-13T08:45:52.032Z","phase":"Phase 1","brief_title":"A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT07159828","lead_sponsor":"Instil Bio","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2025-09-08"},{"id":"27751dcd-f28f-4f36-b8db-e4042ae9fc77","acronym":"CVL006-T1002","url":"https://clinicaltrials.gov/study/NCT07157956","created_at":"2025-09-13T08:47:52.158Z","updated_at":"2025-09-13T08:47:52.158Z","phase":"Phase 1/2","brief_title":"CVL006 Combination Therapy in Advanced Solid Tumors","source_id_and_acronym":"NCT07157956 - CVL006-T1002","lead_sponsor":"Convalife (Shanghai) Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 09/10/2025","start_date":" 09/10/2025","primary_txt":" Primary completion: 08/12/2028","primary_completion_date":" 08/12/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-09-05"},{"id":"2451850f-5b0c-4c08-aeda-4faec51709a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07045311","created_at":"2025-07-05T13:59:45.588Z","updated_at":"2025-07-05T13:59:45.588Z","phase":"Phase 2","brief_title":"JS207 Combination Therapy in Triple-negative Breast Cancer","source_id_and_acronym":"NCT07045311","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • bulumtatug fuvedotin (9MW2821)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 03/22/2028","primary_completion_date":" 03/22/2028","study_txt":" Completion: 03/22/2029","study_completion_date":" 03/22/2029","last_update_posted":"2025-07-01"},{"id":"8260f352-f0e1-4ec2-80e3-a705d1b2d6be","acronym":"","url":"https://clinicaltrials.gov/study/NCT06980272","created_at":"2025-06-28T13:43:54.833Z","updated_at":"2025-06-28T13:43:54.833Z","phase":"Phase 3","brief_title":"SSGJ-707 in Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06980272","lead_sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 06/20/2025","start_date":" 06/20/2025","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-06-24"},{"id":"251e3807-7c32-48ca-b5d8-dd58192012fb","acronym":"DIVON","url":"https://clinicaltrials.gov/study/NCT06957561","created_at":"2025-09-07T01:29:15.570Z","updated_at":"2025-09-07T01:29:15.570Z","phase":"Phase 1/2","brief_title":"Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT06957561 - DIVON","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-05-04"},{"id":"bb6bfd1b-2fa4-443f-a449-16c91a04c63d","acronym":"HARMONi-3","url":"https://clinicaltrials.gov/study/NCT05899608","created_at":"2023-06-12T15:08:54.174Z","updated_at":"2025-02-25T13:55:16.855Z","phase":"Phase 3","brief_title":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients","source_id_and_acronym":"NCT05899608 - HARMONi-3","lead_sponsor":"Summit Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yidafan (ivonescimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 1080","initiation":"Initiation: 10/26/2023","start_date":" 10/26/2023","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-20"},{"id":"89ce58f7-0046-45a6-9589-68bba343777d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05249426","created_at":"2024-03-27T13:37:18.528Z","updated_at":"2025-02-25T14:16:43.633Z","phase":"Phase 1","brief_title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","source_id_and_acronym":"NCT05249426","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/12/2022","start_date":" 04/12/2022","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2025-02-18"},{"id":"972ad6b2-046a-4952-a809-07b8eb832df8","acronym":"CALGB-40503","url":"https://clinicaltrials.gov/study/NCT00601900","created_at":"2021-01-18T02:13:51.918Z","updated_at":"2025-02-25T16:35:58.371Z","phase":"Phase 3","brief_title":"Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer","source_id_and_acronym":"NCT00601900 - CALGB-40503","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER expression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • letrozole • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Soltamox (tamoxifen citrate) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 394","initiation":"Initiation: 09/24/2008","start_date":" 09/24/2008","primary_txt":" Primary completion: 06/30/2014","primary_completion_date":" 06/30/2014","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2025-02-06"},{"id":"b1bfb829-6051-48a2-8e1d-95a6b089f5de","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038396","created_at":"2023-09-14T14:13:03.466Z","updated_at":"2025-02-25T17:39:19.635Z","phase":"Phase 1/2","brief_title":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","source_id_and_acronym":"NCT06038396","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • ciletatug vedotin (RC118)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 08/03/2023","start_date":" 08/03/2023","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-01-29"},{"id":"725d2049-0175-4171-b6e4-a461d540cccf","acronym":"HARMONi-7","url":"https://clinicaltrials.gov/study/NCT06767514","created_at":"2025-02-25T19:17:49.044Z","updated_at":"2025-02-25T19:17:49.044Z","phase":"Phase 3","brief_title":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","source_id_and_acronym":"NCT06767514 - HARMONi-7","lead_sponsor":"Summit Therapeutics","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yidafan (ivonescimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 780","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-01-20"},{"id":"d3c8d101-827f-4797-8f24-69b985eafa2c","acronym":"PRIDE","url":"https://clinicaltrials.gov/study/NCT05871021","created_at":"2023-05-23T16:06:16.277Z","updated_at":"2024-07-02T16:35:09.362Z","phase":"Phase 2","brief_title":"Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma","source_id_and_acronym":"NCT05871021 - PRIDE","lead_sponsor":"Ludwig-Maximilians - University of Munich","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 04/10/2024","start_date":" 04/10/2024","primary_txt":" Primary completion: 04/10/2027","primary_completion_date":" 04/10/2027","study_txt":" Completion: 07/10/2027","study_completion_date":" 07/10/2027","last_update_posted":"2024-04-16"},{"id":"a90bec2f-88ff-4c6c-a913-aab929b35d68","acronym":"","url":"https://clinicaltrials.gov/study/NCT06307925","created_at":"2024-03-13T17:37:31.898Z","updated_at":"2024-07-02T16:35:10.387Z","phase":"Phase 1","brief_title":"A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT06307925","lead_sponsor":"HC Biopharma Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 03/27/2024","start_date":" 03/27/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-04-10"},{"id":"282c5598-a3f1-4e10-8b03-9fef7b6d2b9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03468426","created_at":"2021-01-18T17:05:39.851Z","updated_at":"2024-07-02T16:35:11.588Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours","source_id_and_acronym":"NCT03468426","lead_sponsor":"Boehringer Ingelheim","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 836880"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 05/03/2018","start_date":" 05/03/2018","primary_txt":" Primary completion: 08/06/2024","primary_completion_date":" 08/06/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-04-03"},{"id":"06d625a6-cf6f-4d0a-9c63-1adbf21e5730","acronym":"","url":"https://clinicaltrials.gov/study/NCT01364051","created_at":"2024-03-13T08:33:16.360Z","updated_at":"2024-07-02T16:35:15.340Z","phase":"Phase 1","brief_title":"Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies","source_id_and_acronym":"NCT01364051","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 05/25/2011","start_date":" 05/25/2011","primary_txt":" Primary completion: 06/06/2019","primary_completion_date":" 06/06/2019","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-03-11"},{"id":"d9c9428c-3a59-4384-ad4e-5e3646ac2fde","acronym":"TAVO412","url":"https://clinicaltrials.gov/study/NCT05548634","created_at":"2022-09-21T18:56:21.079Z","updated_at":"2024-07-02T16:35:26.126Z","phase":"Phase 1","brief_title":"A Study of TAVO412 in Patients With Cancer","source_id_and_acronym":"NCT05548634 - TAVO412","lead_sponsor":"Tavotek Biotherapeutics","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MP412 • TAVO412"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/08/2023","start_date":" 05/08/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-15"},{"id":"740d254e-0516-477f-9e11-30abdcd85a7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06016062","created_at":"2023-08-29T16:10:17.223Z","updated_at":"2024-07-02T16:35:27.736Z","phase":"Phase 1","brief_title":"A Study of RC148 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","source_id_and_acronym":"NCT06016062","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 09/14/2023","start_date":" 09/14/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-29"},{"id":"74d0474d-8a4d-4196-856a-9f95d19d924e","acronym":"BIOVAS","url":"https://clinicaltrials.gov/study/NCT04072042","created_at":"2021-01-18T19:56:06.263Z","updated_at":"2024-07-02T16:35:35.004Z","phase":"Phase 2","brief_title":"BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma","source_id_and_acronym":"NCT04072042 - BIOVAS","lead_sponsor":"Ruijin Hospital","biomarkers":" KDR • CSF1R","pipe":"","alterations":" ","tags":["KDR • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/31/2019","start_date":" 08/31/2019","primary_txt":" Primary completion: 02/25/2024","primary_completion_date":" 02/25/2024","study_txt":" Completion: 05/25/2024","study_completion_date":" 05/25/2024","last_update_posted":"2023-10-03"},{"id":"358ec232-22b9-43f3-893c-ffddbf8c3f3c","acronym":"AK112-303","url":"https://clinicaltrials.gov/study/NCT05499390","created_at":"2022-08-14T17:58:07.092Z","updated_at":"2024-07-02T16:35:36.195Z","phase":"Phase 3","brief_title":"AK112 in Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05499390 - AK112-303","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yidafan (ivonescimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 398","initiation":"Initiation: 11/09/2022","start_date":" 11/09/2022","primary_txt":" Primary completion: 06/17/2024","primary_completion_date":" 06/17/2024","study_txt":" Completion: 06/17/2025","study_completion_date":" 06/17/2025","last_update_posted":"2023-09-21"},{"id":"e7b2becf-d2ea-4e6b-ac32-69be2d3a9278","acronym":"AK112-306","url":"https://clinicaltrials.gov/study/NCT05840016","created_at":"2023-05-03T15:04:35.945Z","updated_at":"2024-07-02T16:35:39.169Z","phase":"Phase 3","brief_title":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05840016 - AK112-306","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • Yidafan (ivonescimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 396","initiation":"Initiation: 08/17/2023","start_date":" 08/17/2023","primary_txt":" Primary completion: 12/20/2024","primary_completion_date":" 12/20/2024","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2023-08-23"},{"id":"0b05481d-c3c1-4ad2-939c-6638e0bf26e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01068587","created_at":"2021-01-18T04:12:43.648Z","updated_at":"2025-02-25T13:15:36.669Z","phase":"Phase 1/2","brief_title":"MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy","source_id_and_acronym":"NCT01068587","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • erlotinib • foretinib (GSK1363089)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/21/2010","start_date":" 01/21/2010","primary_txt":" Primary completion: 03/21/2014","primary_completion_date":" 03/21/2014","study_txt":" Completion: 02/13/2015","study_completion_date":" 02/13/2015","last_update_posted":"2023-08-04"},{"id":"87def125-04a6-4b33-bb5e-5e9e6e36a732","acronym":"Endouble","url":"https://clinicaltrials.gov/study/NCT05203276","created_at":"2022-01-24T17:01:44.348Z","updated_at":"2024-07-02T16:35:45.136Z","phase":"Phase 2","brief_title":"Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC","source_id_and_acronym":"NCT05203276 - Endouble","lead_sponsor":"The First People's Hospital of Lianyungang","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab) • Endostar (recombinant human endostatin)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-06-22"}]